| 論文編號: |
|
| 第一作者所在部門: |
|
| 中文論文題目: |
The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies |
| 英文論文題目: |
The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies |
| 作者: |
Diwei Zheng, Xindong Wang, Lin Cheng, Le Qin, Zhiwu Jiang, Ruocong Zhao, Yao Li, Jingxuan Shi, Qiting Wu, Youguo Long, Suna Wang, Zhaoyang Tang, Xinwen Chen, Yao Yao, Lihua Yang and Peng Li |
| 論文出處: |
|
| 刊物名稱: |
Frontiers in Immunology |
| 年: |
2022 |
| 卷: |
13 |
| 期: |
|
| 頁: |
808347 |
| 聯係作者: |
Peng Li |
| 收錄類別: |
|
| 影響因子: |
8.787 |
| 摘要: |
Chimeric antigen receptor (CAR) T cells have been successfully used in the therapy of B cell leukemia and lymphoma, but still have many challenges in their use for treating T cell malignancies, such as the lack of unique tumor antigens, their limitation of T cell expansion, and the need for third party donors or genome editing. Therefore, we need to find novel targets for CAR T cell therapy to overcome these challenges. Here, we found that both adult T-cell leukemia/lymphoma (ATLL) patients and ATLL cells had increased CCR8 expression but did not express CD7. Moreover, targeting CCR8 in T cells did not impair T cell expansionin vitro. Importantly, anti-CCR8 CAR T cells exhibited antitumor effects on ATLL- and other CCR8-expressing T-ALL cellsin vitroandin vivo, and prolonged the survival of ATLL and Jurkat tumor-bearing mouse models. In conclusion, these collective results show that anti-CCR8 CAR T cells possess strong antitumor activity and represent a promising therapeutic approach for ATLL and CCR8+tumors. |
| 英文摘要: |
|
| 外單位作者單位: |
|
| 備注: |
|
